Does sotatercept reduce the risk of death, lung transplantation, or hospitalization in high-risk adults with pulmonary arterial hypertension on maximum tolerated background therapy?
Sotatercept reduces the composite risk of death, lung transplantation, or worsening PAH hospitalization in high-risk patients already on maximal background therapy.
Among high-risk adults with pulmonary arterial hypertension who were receiving the maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of a composite of death from any cause, lung transplantation, or hospitalization (≥24 hours) for worsening pulmonary arterial hypertension than placebo. (Funded by Merck Sharp and Dohme, a subsidiary of Merck Rahway, NJ; ZENITH ClinicalTrials.gov number, NCT04896008.).
“Pooled analyses across trials further suggest that sotatercept may have a meaningful impact on mortality in patients with PAH.”
Humbert et al. (Wed,) studied this question.